Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs

Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sun T

Authors: Sun T, Van Hummelen P, Martin B, Xia C, Zhao L,

Keywords: grade 3, high grade, neuroendocrine carcinoma, whole exome sequencing, rna-seq, transcriptomics, copy number analysis, sequencing, genomics, poorly differentiated,

#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?

Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,

Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,

#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes

Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kong G, Callahan J, Prall O, Michael M, Hicks R,

Keywords: Transformation, G3 NEN, PET imaging, mutation, PRRT, prognosis,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.